MONTOR-LC TABLETS

Tablets

MONTOR-LC TABLETS

PACKING:
48x10x10 tablets

COMPOSITION:
Each uncoated tablet contains:
Montelukast Sodium
I.P.
200 mg
equi. to Montelukast
 
10 mg
Levocetirizine Dihydrochloride     
I.P.     
5 mg
Excipients
 
q.s.
 

DESCRIPTION:
Montor-LC is a combination of Montelukast  Sodium and Levocetrizine. Montelukast Sodium is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene (CysLT1), receptor. Levocetirizine is a third-generation non-sedative antihistamine, developed from the second-generation antihistamine Cetirizine. Chemically, Levocetirizine is the active enantiomer of Cetirizine.

MECHANISM OF ACTION:

Montelukast inhibits bronchoconstriction due to antigen challenge. Montelukast is a selective leukotriene receptor antagonist of the cysteinyl leukotriene CysLT1 receptor. The cysteinyl leukotrienes (LTC 4, LTD 4, LTE 4) are products of arachidonic acid metabolism that are released from various cells, including mast cells and eosinophils. Levocetirizine works by blocking histamine receptors. It does not prevent the actual release of histamine from mast cells, but prevents binding it to its receptors. This in turn prevents the release of other allergy chemicals and increased blood supply to the area, and provides relief.
 
INDICATIONS:
Relief of symptoms of allergic rhinitis (seasonal or perennial), as prophylaxis in seasonal allergic rhinitis and treatment of comorbid asthma.
 
CONTRAINDICATIONS:
Contraindicated in patients with known hypersensitivity to montelukast sodium, levocetirizine or cetirizine or to any other component of this product.
 
SIDE EFFECTS:
Fatigue, dry mouth, dyspepsia, abdominal pain, dizziness, headache, cough, nasal congestion.
 
DOSAGE:
As directed by the physician.
 
STORAGE:
Store in a cool, dry place, away from direct heat and light.
 
PRESENTATION: 10x10 tablets in a cardboard carton

 

0108906044105614
0118906044105611
0128906044105618